Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada.
Ann N Y Acad Sci. 2010 Oct;1207:71-5. doi: 10.1111/j.1749-6632.2010.05801.x.
Currently, many stroke-prone individuals take antithrombotic drugs, which have known antiplatelet properties, to decrease stroke incidence. There is now evidence that this regimen could also reduce stroke severity through neuroprotective, nonplatelet mechanisms that include anti-inflammatory processes. Inflammation was found to play an important role in atherosclerosis/thrombosis development and acute stroke progression. In light of these findings, prevention strategies that target inflammatory mediators are under investigation. A common secondary stroke prevention therapeutic, dipyridamole, has shown promise for reducing stroke recurrence without increasing bleeding. In addition to its antiplatelet ability, dipyridamole has positive effects on vascular endothelium and inflammation. This review explores the effect of dipyridamole during acute stroke, revealing its potential use for improving poststroke clinical outcome.
目前,许多易患中风的个体服用抗血栓药物,这些药物具有已知的抗血小板特性,以降低中风的发生率。现在有证据表明,这种治疗方案还可以通过神经保护、非血小板机制来降低中风的严重程度,其中包括抗炎过程。炎症被发现在动脉粥样硬化/血栓形成的发展和急性中风的进展中起着重要作用。鉴于这些发现,目前正在研究针对炎症介质的预防策略。一种常见的二级中风预防治疗药物,双嘧达莫,已显示出降低中风复发而不增加出血的潜力。除了其抗血小板作用外,双嘧达莫对血管内皮和炎症也有积极的影响。本综述探讨了双嘧达莫在急性中风期间的作用,揭示了其在改善中风后临床结局方面的潜在用途。